Stockscreener 앱 받기
2.87
0.69%
-0.02
전일 마감가:
$2.89
열려 있는:
$2.9
하루 거래량:
136.42K
Relative Volume:
0.65
시가총액:
$171.86M
수익:
-
순이익/손실:
$-40.33M
주가수익비율:
-1.6034
EPS:
-1.79
순현금흐름:
$-39.53M
1주 성능:
-0.69%
1개월 성능:
-4.33%
6개월 성능:
-28.25%
1년 성능:
+2.50%
1일 변동 폭
$2.87
$2.97
1주일 범위
$2.8201
$3.16
52주 변동 폭
$2.30
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
명칭
Eledon Pharmaceuticals Inc
전화
949-238-8090
주소
19800 MACARTHUR BLVD., IRVINE
ELDN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.87 | 173.06M | 0 | -40.33M | -39.53M | -1.79 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Guggenheim | Buy |
| 2022-05-13 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 개시 | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc 주식(ELDN)의 최신 뉴스
Cantor Fitzgerald maintains Overweight on Eledon Pharmaceuticals stock By Investing.com - Investing.com UK
Tower Research Capital LLC TRC Purchases 6,412 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Eledon (ELDN) Advances Tegoprubart for Organ Transplant Therapy - GuruFocus
Eledon (ELDN) Advances Tegoprubart for Organ Transplant Therapy | ELDN Stock News - GuruFocus
Eledon Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results - The Manila Times
Barclays PLC Makes New $288,000 Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Eledon Pharmaceuticals (ELDN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Eledon Pharmaceuticals Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet - Seeking Alpha
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has caught the attention of institutional investors who hold a sizeable 46% stake - Yahoo Finance
Geode Capital Management LLC Buys 285,043 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Eledon Pharmaceuticals appoints Deloitte as new auditor By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals appoints Deloitte as new auditor - Investing.com
Charles Schwab Investment Management Inc. Purchases 15,000 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Virtu Financial LLC Takes $82,000 Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) - Defense World
Is Eledon Pharmaceuticals (ELDN) The Hot Biotech Stock Under $5? - Yahoo
Equities Analysts Set Expectations for ELDN FY2025 Earnings - Defense World
Research Analysts Set Expectations for ELDN FY2025 Earnings - Defense World
What is Leerink Partnrs’ Forecast for ELDN Q1 Earnings? - Defense World
Eledon Pharmaceuticals Reports 2024 Financial Results and Clinical Advances - MSN
We're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash Wisely - Yahoo
10 Hot Biotech Stocks Under $5 - Insider Monkey
Eledon Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Eledon Pharmaceuticals Inc. (ELDN) reports earnings - Quartz
Eledon Pharmaceuticals FY Operating Expenses USD 70.577 Million -March 20, 2025 at 04:48 pm EDT - Marketscreener.com
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results - The Manila Times
Eledon Achieves Historic Transplant Milestones as Cash Position Hits $140M - StockTitan
Eledon Pharmaceuticals (ELDN) to Release Earnings on Thursday - Defense World
Institutional investors in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) see US$25m decrease in market cap last week, although long-term gains have benefitted them. - Simply Wall St
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - GlobeNewswire
When Can You Hear Eledon's Latest Strategic Updates? Key Conference Appearance Scheduled - StockTitan
Eledon Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Eledon Touts Tegoprubart Used in Pig Kidney Transplant - Orange County Business Journal
Before You Invest, Make Sure You Check This Eledon Pharmaceuticals Inc (NASDAQ: ELDN) Analysis - Stocks Register
Leerink Partnrs Has Pessimistic Outlook of ELDN Q4 Earnings - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for ELDN Earnings - Armenian Reporter
Eledon's tegoprubart used in second pig-to-human kidney transplant - MSN
Leerink Partnrs Issues Negative Outlook for ELDN Earnings - Defense World
Eledon's tegoprubart used in second pig-to-human kidney transplant By Investing.com - Investing.com South Africa
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key - GlobeNewswire
Eledon announces tegoprubart use in transplant of pig kidney into human - TipRanks
Revolutionary Xenotransplant Success: Eledon Drug Enables Patient Freedom from Dialysis - StockTitan
FY2029 Earnings Estimate for ELDN Issued By Leerink Partnrs - Armenian Reporter
Eledon Pharmaceuticals Inc (ELDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):